624. Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Immunotherapy Approaches in Hodgkin Lymphoma
Conclusion cited from the abstract:
Although the study did not meet its primary endpoint, our data demonstrate that 3 cycles of PEM is highly active in pts with newly diagnosed early unfavorable or advanced stage cHL. PEM monotherapy resulted in > 90% reduction in TMV in the majority of pts, and when followed by AVD x’s 2, CR in 100%. No pts have experienced progression or change of therapy to date and treatment was overall very well tolerated. This radiotherapy- and bleomycin-free approach warrants further investigation in larger trials to confirm response rates and assess efficacy compared with other novel combinations in the frontline setting.
Paul Jan Bröckelmann, et al.
Conclusion cited from the abstract: Concomitant and sequential therapy with nivolumab and AVD is feasible with acceptable toxicity. In early-stage unfavorable cHL, concomitant Nivo-AVD induces a high early CR rate. The interim CR rate observed with 4x nivolumab monotherapy is higher than previously reported in relapsed or advanced-stage disease. The primary endpoint and initial PFS data will be reported at the meeting.
Christopher A. Yasenchak, et al.
Conclusion cited from the abstract: Elderly HL remains an unmet clinical need. These data suggest that BV + Nivo is an active treatment with an encouraging CR rate (72%) and appears well tolerated in these patients. These results also suggest that with further follow-up and validation, treatment with BV + Nivo may improve patient outcomes. Enrollment in this cohort is complete (21 subjects), with 7 subjects continuing to receive treatment.
Conclusion cited from the abstract: BV + Nivo, both staggered and current dosing, showed tolerability and high CR rates with durable remissions among pts with R/R cHL. Analysis of blood biomarkers identified trends potentially linking baseline levels of CD30+ immune cells and the baseline pt inflammatory state with the activity of BV + Nivo. Together, these encouraging results support further investigation of BV + Nivo as initial salvage therapy in pts with R/R cHL.
Conclusion cited from the abstract: PET-adapted nivo followed by NICE in patients without CR is a well-tolerated and effective first salvage approach in pts with RR HL. In our cohort, nivo alone was an effective bridge to ASCT in a majority of pts, sparing them the toxicity of traditional salvage chemotherapy. Pts who did not achieve CR with nivo were effectively salvaged by NIVO+ICE
Conclusion cited from the abstract: With a median of 39.5 mo of follow-up, pembro continued to demonstrate clinically important antitumor activity in pts with R/R cHL. In the total population and in pts with different treatment histories, ORRs were high and responses were durable. Second-course pembro was able to re-induce remission in most patients who previously reached CR. Safety was manageable, and no unexpected AEs occurred.